India Cdsco Medical Device Registration Consultant

Scope and evidence must be confirmed before any paid tests or filings.

What a CDSCO registration consultant must decide before filing

The first deliverable is a defensible regulatory route, not a completed application. Confirm whether the product is a medical device under India’s notified definition, its exact intended medical purpose, whether it is an in-vitro diagnostic (IVD), and whether it will be imported or manufactured locally. A CE mark, US authorization or ISO certificate does not itself authorize Indian market entry.

Under the Medical Devices Rules, 2017 (MDR), CDSCO classifies devices by risk as A, B, C or D using the First Schedule and its published, amendable classification lists. Compare your exact claims, design, duration and manner of use with those entries; do not infer Indian class solely from an overseas class. If the product is absent or ambiguous, prepare labels, instructions for use (IFU), technical description and overseas regulatory status for a classification request to CDSCO before committing to a licence pathway.

Route-selection matrix: commercial activity × class × exception

Use this as a preliminary routing screen, not as an approval. The competent authority and application depend on the specific device and business activity.

Situation	Regulatory starting point	Decision that can change the route
Import of a licensed device (A–D, except qualifying A NSNM)	Central Licensing Authority: import application MD-14; licence MD-15.	Check India risk class, Indian authorised agent and manufacturing-site scope.
Indian manufacture: Class A requiring licence or Class B	State Licensing Authority for the manufacturing premises; ordinary manufacture MD-3 → MD-5.	Verify site, product, QMS and whether a loan-licence arrangement applies.
Indian manufacture: Class C or D	Central Licensing Authority; ordinary manufacture MD-7 → MD-9.	Resolve higher-risk evidence and site inspection planning before filing.
Class A, non-sterile AND non-measuring (NSNM)	Exempt from the normal import/manufacture licensing route, but online device registration number is required.	A sterile or measuring variant does not qualify merely because a related model appears on the list.
No-predicate (investigational) medical device	Assess prior permission under MDR rule 63 (MD-26 → MD-27) before the applicable ordinary licence; MD-14 alone is not a complete route.	Determine whether a predicate exists and whether any clinical-data relief actually meets every rule 63 condition.
IVD: ordinary versus new	Classify the IVD separately. An ordinary IVD follows its class/activity licence route; a new IVD needs the special rule 64 permission (MD-28 → MD-29), in addition to the applicable licensing analysis.	Check intended diagnostic purpose, classification and whether the product is a new IVD, rather than treating all IVDs as novel.

A CDSCO notice dated 31 October 2025 publishes a dynamic list for Class A NSNM. This is not a blanket exemption from regulation: matching intended use, non-sterile/non-measuring characteristics, online registration, labelling and applicable standards still require checking. The general requirement for an import or manufacturing licence applies outside the relevant exception.

2026 amendment — registration-only does not mean QMS-free. G.S.R. 744(E) amended rules 19H(2)(v) and 19J(2)(v): a manufacturer or importer registering a qualifying Class A NSNM device must self-certify compliance with applicable standards AND the Quality Management System. Verify the relevant QMS arrangements and support for the declaration before using the online route; the amendment does not itself impose a specified third-party QMS certificate or replace registration with an ordinary device import/manufacturing licence.

Six-input triage file: what to ask the manufacturer first

Request an evidence index, not hundreds of unlabelled files. Each input below must answer an explicit strategic question.

Input to collect	What to verify	Decision enabled
Claims, IFU, label and target users	Diagnostic/therapeutic purpose; patient contact; invasiveness; intended duration.	Regulatory scope, risk class and potential classification referral.
SKU/variant tree and configuration	Sterile status, measurement, software function, accessories, pack and model differences.	Which variants can share a route and which need separate evaluation.
Actual and legal manufacturing sites	Site addresses, manufacturer identity, outsourced steps, intended Indian activity.	Import versus manufacture; site scope; responsible licensing authority.
India importer/agent particulars	Indian entity, eligible manufacturing/wholesale/MD-42 status, proposed power of attorney.	Whether the proposed authorised agent can serve as applicant.
Existing evidence inventory	Plant/Device Master Files, QMS, risk, test/performance/clinical data, approvals and certificates.	Which records can be reused and which require India-specific bridging.
Market and change history	Indian licences already held, earlier agents, pending design/site/label changes.	New application versus endorsement or change assessment.

Gap analysis: reuse evidence without mistaking it for approval

Run a four-column gap register: Indian requirement; existing evidence and version; verified match or unresolved discrepancy; owner and next action. Start with the device’s intended use and class, then inspect Plant Master File and Device Master File content under the Fourth Schedule, quality-system evidence, applicable standards, performance or clinical support, and India-specific labels/IFU.

A foreign technical file is an evidence source, not a substitute for the Indian dossier. Reuse testing only after checking device/model identity, test method and version, scope, acceptance criteria and whether the MDR route demands further data. Decide whether a predicate is genuinely comparable before planning a novel-device submission. Do not order fresh testing simply because a document has a foreign title.

Use three dispositions for every gap: REUSE (traceable and applicable), BRIDGE (update, cross-reference, translate or justify), or GENERATE (new study, test or document after confirming the requirement). Mark unresolved classification or clinical-data questions as STOP, not assumed exemptions.

For devices without a predicate, the 2026 amendment to rule 63(1), fourth proviso, adds EU countries to the listed foreign jurisdictions. The possibility of not submitting clinical-investigation results is conditional: the device must have the specified foreign approval, at least two years of marketing there, CDSCO satisfaction with safety, performance and vigilance data, no relevant expected difference in the Indian population, and an undertaking for an approved post-marketing clinical investigation. This is neither automatic recognition of CE marking nor an exemption from the separate no-predicate permission assessment. Ordinary IVD classification is likewise distinct from the special new-IVD permission route. Outsourced sterilisation is a separate 2026 label-and-supplier gate. Under G.S.R. 743(E), rule 44(p) calls for the valid manufacturing-licence number of the outsourced sterilisation site on the device label; compliance becomes mandatory six months after the notification dated 14 August 2026. Record the outsourced facility and its licence before approving label artwork. The same amendment adds a Ninth Schedule of prescribed test/evaluation fees for rules 19 and 69; do not mistake that schedule for a universal private laboratory quotation. The required licence number must be preceded by a designation allowed in the Gazette: “Sterilization sites Manufacturing License Number”, “Ster. Mfg. Lic. No.” or “S.M. L.”; verify the exact label artwork against rule 44(p).

Consultant, authorised agent and licence holder are different roles

For imports, the overseas manufacturer appoints an Indian authorised agent through a power of attorney. CDSCO identifies eligibility via an appropriate manufacturing/wholesale licence or MD-42 registration, subject to the applicable rules. A consultancy agreement alone does not make the consultant the authorised importer or licence holder; verify the applicant entity and documentary authority separately.

The licensed holder retains regulatory responsibilities, including post-market surveillance information. Ask the consultant for a signed route memo, class rationale, evidence-gap register, responsibility allocation and documented unresolved assumptions. Only a person authorised by the company may seek application status from the authority, according to CDSCO’s FAQ. No consultant can promise an approval outcome.

Pre-filing decision gates and a realistic stop/go point

A useful advisory engagement ends with an approved strategy memo that fixes the route before anyone commissions work or submits fees:

Freeze device identity, claims and the SKU list; identify IVD, software, accessory and sterile/measuring variants.
Document class rationale against the latest CDSCO list; request CDSCO classification if unresolved.
Select import/manufacture/qualifying NSNM or a special-permission path; confirm authority and applicant.
Review reusable evidence and issue a ranked gap register with owners, dependencies and cost drivers.
Authorize only necessary remedial work; then transfer the agreed scope to the filing team.

STOP if classification, legal applicant, actual manufacturing site or clinical/performance evidence cannot be substantiated. Neither a portal entry nor an overseas clearance removes that uncertainty. Quote budgets in separately identified regulatory fees, laboratory/site work and consultant charges; do not invent universal timelines.

When an existing Indian licence or another importer changes the answer

An earlier MD-15 for the same product does not automatically transfer to a new agent. CDSCO describes separate documentation for subsequent importers, with potential reuse of an unchanged Plant/Device Master File where the manufacturer supplies the specified undertaking. Change of Indian authorised agent requires a fresh import licence; certain changes involving the licensee’s constitution, the overseas manufacturer executing the power of attorney or the actual manufacturing-site location also trigger fresh-licence assessment. Product additions, changed labels or variants require their own change/endorsement review.

Advisory output versus registration execution

This page owns the route memo, class rationale, risk register and evidence-reuse decisions. For application packaging, submission and follow-up, see India CDSCO medical device registration service. For detailed IVD filing, see India CDSCO registration service for IVD devices. For non-medical product regimes, see product compliance and market access in India. The next safe action is to obtain the six-input triage file and resolve all STOP items before appointing a filing team.

FAQ: decisions that can derail an India CDSCO strategy

Can I use my European or US class to select the Indian application?

No automatic equivalence. Compare intended use and risk criteria with CDSCO’s current Indian lists. If absent or ambiguous, seek clarification with product technical documents rather than guess.

Does every Class A product avoid an import/manufacturing licence?

No. The specific exception covers qualifying Class A devices that are both non-sterile and non-measuring; they still require online registration and applicable labelling/standards checks.

Can a regulatory consultant file as our Indian importer without being appointed?

No. Identify an eligible Indian applicant and the overseas manufacturer’s power of attorney. Consulting and legal agent status must not be conflated.

Can we reuse a previous importer’s approved device dossier?

Potentially, within CDSCO’s conditions for a subsequent importer and documented manufacturer undertaking confirming unchanged files; it is not automatic licence transfer.

Should we book testing before fixing the class and predicate position?

Usually not. First map existing evidence to the selected Indian route; a novel or IVD-specific pathway may demand different performance or clinical support.